DelveInsight’s Chronic Venous Insufficiency pipeline report provides an in-depth analysis of the current clinical development landscape and growth prospects for the Chronic Venous Insufficiency industry. The disease summary and Chronic Venous Insufficiency therapy instructions are included in a complete depiction of the Chronic Venous Insufficiency pipeline landscape.
Some of the Important Findings from the Chronic Venous Insufficiency Pipeline Report
The Chronic Venous Insufficiency pipeline comprises therapies, as well as devices that are in different stages of the clinical phase, include Sulodexide, TR 987, P-TEV, EndoVenous Valve System (EVVS), InnoVein Valve Treatment, BioVena, VenoValve, and others that are anticipated to launch in the upcoming year and join the Chronic Venous Insufficiency treatment market soon.
Key MedTech and pharmaceutical companies involved in developing novel therapies and medical devices for Chronic Venous Insufficiency include Alfasigma, SerenaGroup, Verigraft AB, Venarum Medical, Innovein, Venari Medical, Hancock Jaffe Laboratories, among others.
Chronic Venous Insufficiency pipeline therapies that are in late phases i.e Phase III include Sulodexide (Alfasigma), and others whereas TR 987 (SerenaGroup) is in Phase II of clinical trials for Chronic Venous Insufficiency treatment.
P-TEV is being developed and investigated in Phase I studies by Verigraft AB for Chronic Venous Insufficiency treatment.
Request for the sample to reach out for more @ Chronic Venous Insufficiency Pipeline Analysis
Chronic Venous Insufficiency: Overview
Chronic Venous Insufficiency (CVI) is a term used to describe lower extremity edema, skin trophic changes, and discomfort caused by venous hypertension. The pathophysiology of chronic venous insufficiency is caused by either reflux (backward flow) or obstruction of venous blood flow. Chronic venous insufficiency can develop as a result of long-term valvular incompetence in the superficial veins, deep veins, or perforating veins that connect them. The end result is venous hypertension of the lower extremities in all cases.
Chronic Venous Insufficiency Symptoms
The most common Chronic Venous Insufficiency symptoms are:
Tight feeling in calves or itchy
Painful legs
Swelling in legs or ankles
Painful leg cramps or muscle spasms
Varicose veins
Leg ulcers
Chronic Venous Insufficiency Treatment
The Chronic Venous Insufficiency treatment focuses on controlling the retrograde flow of blood, venous pooling, and the complications associated with these pathophysiologic processes. Conservative treatment consists of dietary changes, compression therapy with devices, and the administration of venoactive drugs (venopharmaceuticals).
Chronic Venous Insufficiency Pipeline Analysis: Drug Profile
TR 987: SerenaGroup
Product Description
TR-987 (formerly GLYC-101) is an insoluble, microparticulate (13)(16)-glucan extracted from yeast cells in a specific configuration and size. TR-987’s active pharmaceutical ingredient is Glucoprime, a type of glucan known as particulate (1→3)(1→6)-β-glucan.
Phase II
NCT03154619: SerenaGroup, in collaboration with TR Therapeutics, launched a multi-center, randomized, double-blind, placebo-controlled study in November 2016 to assess the efficacy of TR 987 gel in the treatment of chronic venous insufficiency ulcers.
Chronic Venous Insufficiency Pipeline Analysis: Medical Device Profile
VenoValve: Hancock Jaffe Laboratories
VenoValve is a bioprosthetic venous valve that improves chronic lower extremity venous reflux via an open surgical procedure. The company is conducting a prospective, non-blind, single-arm, multicenter study to evaluate the safety and efficacy of the VenoValve, which is surgically implanted into the deep venous system to treat patients with deep venous valvular insufficiency.
Chronic Venous Insufficiency Pipeline Therapies/Devices and Key Companies
Sulodexide: Alfasigma
P-TEV: Verigraft AB
EndoVenous Valve System (EVVS): Venarum Medical
InnoVein Valve Treatment: Innovein
BioVena: Venari Medical
For more information on the emerging drugs/devices and companies, visit Chronic Venous Insufficiency Clinical Trails
Chronic Venous Insufficiency Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase III
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
Protease
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Multiple Kinase Inhibitor
Chronic Venous Insufficiency Medical Device Assessment
Pre-clinical
Clinical
By Patient Type
Pediatric
Adult
Scope of the Report
Coverage: Global
Chronic Venous Insufficiency Key Players: Alfasigma, SerenaGroup, Verigraft AB, Venarum Medical, Innovein, Venari Medical, Hancock Jaffe Laboratories, among others
Chronic Venous Insufficiency Pipeline Therapies/Devices: Sulodexide, TR 987, P-TEV, EndoVenous Valve System (EVVS), InnoVein Valve Treatment, BioVena, VenoValve, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
4.
Chronic Venous Insufficiency Pipeline Therapeutics
5.
Chronic Venous Insufficiency Late Stage Products (Pre-registration)
6.
Chronic Venous Insufficiency Late Stage Products (Phase III)
7.
Chronic Venous Insufficiency Mid Stage Products (Phase II)
8.
Chronic Venous Insufficiency Early Stage Products (Phase I)
9.
Chronic Venous Insufficiency Pre-clinical and Discovery Stage Products
10.
Chronic Venous Insufficiency Pipeline Medical devices: Company Profiles
11.
Chronic Venous Insufficiency Therapeutic Assessment
12.
13.
Chronic Venous Insufficiency Inactive Products
14.
Chronic Venous Insufficiency- Market Drivers and Barriers
15.
Chronic Venous Insufficiency- Unmet Needs
16.
Appendix
17.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Key questions answered in the Chronic Venous Insufficiency Pipeline Report
What are the available treatments for Chronic Venous Insufficiency?
How many pharmaceutical and Medtech companies are developing treatments for Chronic Venous Insufficiency?
Which of these firms’ pharmaceuticals is the most widely used?
How many Chronic Venous Insufficiency medications/devices does each company produce?
How many drugs/devices for Chronic Venous Insufficiency are in the early, mid, or late stages of development?
How many of the currently being developed therapies/devices can be used alone or in combination with other treatments?
What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices affecting Chronic Venous Insufficiency?
Related Reports
Exocrine Pancreatic Insufficiency Pipeline Insights
Get a comprehensive analysis of Exocrine Pancreatic Insufficiency pipeline therapies and key companies including Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/